Showing 6181-6190 of 8828 results for "".
- Innocutis Introduces Cold Sore Dissolvable Tablet to North American Markethttps://practicaldermatology.com/news/20140722-innocutis_introduces_cold_sore_dissolvable_tablet_to_north_american_market/2459160/Innocutis recently introduced Sitavig ®(ACYCLOVIR) 50mg Buccal Tablet to North American markets for the treatment of herpes labialis. Sitavig uses a proprietary delivery technology which consists of a tasteless and odorless tablet that sticks to the gum above the incisor tooth on the side of the lip
- Psoriasis Foundation Awards 13 Research Fellowshipshttps://practicaldermatology.com/news/20140721-psoriasis_foundation_awards_13_research_fellowships/2459162/The National Psoriasis Foundation awarded 13 residents and medical students each a one-year, $50,000 fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the study
- Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of Kerydin in the UShttps://practicaldermatology.com/news/20140721-anacor_pharmaceuticals_and_sandoz_enter_into_an_agreement_for_the_commercialization_of_kerydin_in_the_us/2459163/Anacor Pharmaceuticals, Inc. has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize Anacor's recently approved Kerydin (tavaborole) topical solution, 5% in the US. PharmaDerm, the branded dermatology business of Sandoz
- Benefits of Multi-beam OCT Presented at the 24th Annual Education Week for Practical Dermatology and Venereologyhttps://practicaldermatology.com/news/20140718-benefits_of_multi-beam_oct_presented_at_the_24th_annual_education_week_for_practical_dermatology_and_venereology/2459164/Michelson Diagnostics, a UK based medical device company, announced that a session on the benefits of the multi-beam OTC —"Evidence for OCT diagnostics" — will be presented during the 24th Annual Education Week for Practical Dermatology and Venereology, known as Fortbildungswoche, in Munich, Germ
- Regeneron and Sanofi Announce Positive Results from Phase IIb Study of Dupilumab for Atopic Dermatitishttps://practicaldermatology.com/news/20140715-regeneron_and_sanofi_announce_positive_results_from_phase_iib_study_of_dupilumab_for_atopic_dermatitis/2459168/Regeneron Pharmaceuticals, Inc. and Sanofi announced positive results from a Phase IIb dose-ranging study of dupilumab for moderate to severe atopic dermatitis. All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scor
- MELA Sciences Begins Insurance Reimbursement Process With Application for New CPT Code for the MelaFind Systemhttps://practicaldermatology.com/news/20140715-mela_sciences_begins_insurance_reimbursement_process_with_application_for_new_cpt_code_for_the_melafind_system/2459170/MELA Sciences, Inc. (Nasdaq:MELA), announced today that it has taken the first step in the process of seeking insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (MSDSLA) procedure that is performed by dermatologists utilizing the MelaFind® system as an aid in the detection o
- Advanced Dermatology & Cosmetic Surgery (ADCS Clinics) Acquires The Grekin Skin Institutehttps://practicaldermatology.com/news/20140714-advanced_dermatology__cosmetic_surgery_adcs_clinics_acquires_the_grekin_skin_institute/2459172/ADCS Clinics ("ADCS") announced it has completed the acquisition of The Grekin Skin Institute in Southfield, Michigan, a dermatology practice founded by Dr. Steven Grekin.
- KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New Drug Applicationhttps://practicaldermatology.com/news/20140711-kythera_biopharmaceuticals_announces_fda_acceptance_of_atx-101_new_drug_application/2459173/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the FDA's determination that the application is sufficien
- PuraCap Pharmaceutical Introduces EpiCeram 225g Airless Pumphttps://practicaldermatology.com/news/20140711-puracap_pharmaceutical_introduces_epiceram_225g_airless_pump/2459174/PuraCap Pharmaceutical introduced the newest addition to the EpiCeram product line, the EpiCeram 225g Airless Pump. The airless pump gives patients more EpiCeram to treat any size area of atopi
- Registration Open for Upcoming ADAM Webinarshttps://practicaldermatology.com/news/20140708-registration_open_for_upcoming_adam_webinars/2459177/The Association of Dermatology Administrators and Managers (ADAM) is offering webinars for practice administrators